AHA officials penned a Medical Economics op-ed on “the truth behind growth of the 340B prescription drug program.”
AHA Raises ‘Serious Concerns’ with MedPAC’s Direction on 340B
A major hospital advocacy group recently urged congressional advisers to “carefully consider” the potential negative consequences of any new efforts [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.